EOFlow Officially Launches iOS Version of the EOPatch App ‘Narsha’
EOFlow Announces Record Revenue for First Quarter 2022; Revenue of 949 Million KRW which is 137% of Last Year’s Annual Revenue
EOFlow Has its First Clinical Study on EOPatch Published in Diabetes & Metabolism Journal
EOFlow to Supply KRW48.8bn Worth of EOPatch to Gulf Drug of UAE
EOFlow announces two clinical study plans supported by Korean government
EOFlow publishes the final report on its first clinical trial
EOFlow goes IPO
EOFlow Selected as a 2019 Red Herring Top 100 Asia Winner
EOFLOW Chosen as Company of the Year
Menarini Diagnostics & EOFlow sign a long term business agreement
Improved EOPatch is approved in Korea
EOFLOW Receives Breakthrough Device Designation from FDA
EOFLOW presents at Diabetes Technology Meeting
EOFLOW awarded at Start-Up Festival 2018